DDInter708 DDInter927
Ezogabine (D23129) is a close structural analog of the centrally acting analgesic flupitrine. It is a neuronal potassium channel opener being developed as a first-in-class antiepileptic drug (AED) and is currently being studied in Phase 3 trials as an adjunctive treatment for partial-onset seizures in adult patients with refractory epilepsy. FDA approved in June 10, 2011 under the name of ezogabine.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Ezogabine {u} (Compound) resembles {v} (Compound) Flupirtine
Ezogabine {u} (Compound) binds {v} (Gene) UGT1A1
Ezogabine {u} (Compound) is included by {v} (Pharmacologic Class) Potassium Channel Openers
Ezogabine {u} (Compound) causes {v} (Side Effect) Ill-defined disorder
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Ezogabine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Palonosetron
Ezogabine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Encorafenib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Ezogabine {u} may lead to a major life threatening interaction when taken with {v} Crizotinib
Ezogabine (Compound) resembles Flupirtine (Compound)
Ezogabine (Compound) binds UGT1A1 (Gene)
Ezogabine (Compound) is included by Potassium Channel Openers (Pharmacologic Class)
Ezogabine (Compound) causes Ill-defined disorder (Side Effect)
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Ezogabine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Palonosetron
Ezogabine may cause a moderate interaction that could exacerbate diseases when taken with Encorafenib
Ezogabine may lead to a major life threatening interaction when taken with Nilotinib
Ezogabine may lead to a major life threatening interaction when taken with Crizotinib